Modulation of the tumor disposition of vinca alkaloids by psc 833 in vitro and in v/vo

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 3, 1998, Pages 963-968

  Song, Saeheum ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN DERIVATIVE; GLYCOPROTEIN P; VALSPODAR; VINBLASTINE; VINCRISTINE; VINCA ALKALOID;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; METABOLISM; MOUSE; NUDE MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; COLORECTAL TUMOR; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOSPORINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VINBLASTINE; VINCRISTINE;

EID: 0032253671     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Belle SJ-PV, Smet DM, Neve WD, Monsaert C, Storme GA and Massart DL (1992) Determination of vinca alkaloids in mouse tissue by high-performance liquid chromatography. J Chromatogr 578:223-229.
2. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH and Bleehen NM (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618.
3. Broxterman HJ, Feller N, Kuipper CM, Versantvoort CHM, Teerlink T and Pinedo HM (1995) Correlation between functional and molecular analysis of mdrl Pglycoprotein in human solid-tumor xenografts. Int J Cancer 61:880-886.
4. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR and Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
5. Cufer T, Vrhovec I, Skrk J, Pfeifer M, Pajk B, Zakotnik B, Filipic B, Rode B and Sikic Bl (1995) Cyclosporin A increases serum cortisol levels in rabbits. Anticancer Drugs 6:615-618.
6. Colombo T and Gonzalez PO (1996) Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 73:866-871.
7. Cros S, Guilbaud N, Berlion, M, Dunn, T, Régnier, G, Dhainaut, A, Atassi, G. and Bizzari JP (1992) In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model. Cancer Chemother Pharmacol 30:491-494.
8. Didier AD and Loor F ( 1996) Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer 67:435-440.
9. Ellis AG, Crinis NA and Webster LK (1996) Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 38:81-87.
10. Hamada H and Tsuruo T (1986) Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sei USA 83:7735-7789.
11. Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME and Houghton PJ (1989) Modulation by verapamil of VCR pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 38:1727-1736.
12. Iwahashi T, Okochi E, Ariyoshi K, Watabe H, Amann E, Mori S, Tsuruo T and Ono K (1993) Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human col<>rectal carcinoma cell lines in the nude mouse model. Cancer Res 53:5475-5482.
13. Jette L, Murphy GF, Leclerc JM and Beliveau R (1995) Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 50:1701-1709.
14. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA and Hiestand PC (1992a) Pharmacologie interactions between the resistance-modifying cyclosporin SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51:433-438.
15. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P and Hiestand PC (1992b) SDZ PSC 833, a nonimmunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of mûrir e leukemia. Int J Cancer 50:593-597.
16. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M and Sugiyama Y (199'') P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283:574-580.
17. Lemaire M, Bruelisauer A, Guntz P and Sato H (1996) Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 38:481-486.
18. Ludescher C, Eisterer W, Hübe W, Hofmann J and Thaler J (1995) Decreased potency of MDR-modulators under serum conditions determined by functional assay. Br J Haematol 91:652-657.
19. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J and Sikic BI (1993) Clinical trials of modulation of multidrug resistance: Pharmacokinetic and pharmacodynamic considerations. Cancer (Suppl) 72:3502-3514.
20. Mano Y, Suzuki H, Terasaki T, Iwahashi T, Ono K, Naito M, Tsuruo T, Sugiyama Y (1997) Kinetic analysis of the disposition of MRK16, an anti-P-glycoprotein monoclonal antibody, in tumors: Comparison between in vitro and in vivo disposition. 7 Phamacol Exp Ther 283:391-401.
21. Nelson RL (1982) The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine and vinblastine in human patients with cancer. Med Pediatr Oncol 10:115-127.
22. Pastan I and Gottesman MM (1987) Multi-drug resistance in human cancer. NEngl J Med 316:1388-1393.
23. Raderer M and Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553-3563.
24. Reynolds EF (1996) Matindals'e The Extra Pharmacopoeia, 31th éd., pp. 606-607, The Royal Pharmaceutical Society, London.
25. Schinkel AH, Wagenaar E, Deemter LV, Mol CAAM and Borst P (1995) Absence cf the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Invest 96:1698-1705.
26. Schinkel AH, Smit JJM, Teiligen OV, Beijnen JH, Wagenaar E, Deemter LV, Mcl CAAM Valk MAVD, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P ( 1994) Disruption of the mouse mdrla P-gluycoprotein gene leads to a deficiency in the blood-brain barrier and increased sensitivity to drugs. Cell 77:491-502.
27. Song SH, Suzuki H, Kawai R, Tanaka C, Akasaka I and Sugiyama Y (1998) Dosedependent effect of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab Dispos 26:1128-1133.
28. Spoelstra EC, Dekker H, Schuurhuis GJ, Broxterman HJ and Lankelma J (1991) P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic dru; resistance in various colon cancer cell lines: Evidence for a saturation of active daunorubicin transport. Biochem Pharmacol 41:349-359.
29. Tellingen OV, Beijnen JH, Nooijen WJ and Bult A (1993) Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography. Cancer Chemother Pharmacol 32:286-292.
30. Watanabe T, Miyauchi S. Sawada Y, Iga T, Hanano M, Inaba M and Sugiyama 7 (1992) Kinetic analysis of hepatobiliary transport of VCR in perfused rat liver: Possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol 16: 77-88.
31. Watanabe T, Suzuki H. Sawada Y, Naito M, Tsuruo T, Inaba M, Hanano M and Sugiyama Y (1995a) Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J Hepatol 23:440-448.
32. Watanabe T, Tsuge H, Oh-Hara T, Naito M and Tsuruo T (1995b) Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34:235-241.
33. Watanabe T, Nakayama Y, Naito M, Oh-hara T, Itoh Y and Tsuruo T (1996) Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anti-Cancer Drugs 7:825-832.
34. Wierzba K, Sugiyama Y, Iga T and Hanano M (1988) Kinetic study on the mechanism of tissue distribution of vinblastine. J Pharmacobiodyn 11:651-661.
35. Wierzba K, Sugiyama Y, Okudaira K, Iga T and Hanano M (1987) Tubulin as a major determinant of tissue distribution of vincristine. J Pharm Sei 76:872-875.